CEL-SCI'S Multikine Reduced 5-year Death Rate From 54% to 22% in Phase 3 Study Patients Who Were Early Tumor Responders Prior to Any Standard of Care Treatment
Stock Information for Cel-Sci Corporation
Loading
Please wait while we load your information from QuoteMedia.